Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Todd N Eagar

Showing results (11-20 of 53) with videos related to

Pageof 6
Sort By:
JAMA|October 29, 2009
DNA beta-amyloid(1-42) trimer immunization for Alzheimer disease in a wild-type mouse modelDoris Lambracht-Washington, Bao-Xi Qu, Min Fu, et al.
Journal of the Neurological Sciences|August 21, 2007
Prion proteins: physiological functions and role in neurological disordersWei Hu, Bernd Kieseier, Elliot Frohman, et al.
Plos One|August 9, 2018
Presenilin1 regulates Th1 and Th17 effector responses but is not required for experimental autoimmune encephalomyelitisMatthew Cummings, Anitha Christy Sigamani Arumanayagam, Picheng Zhao, et al.
Clinical Transplantation|March 20, 2023
Deceased donor vein extension grafts for right living donor kidney transplantationAndrea M Meinders, Richard Knight, Todd N Eagar, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 10, 2004
CTLA-4 regulates expansion and differentiation of Th1 cells following induction of peripheral T cell toleranceTodd N Eagar, Danielle M Turley, Josette Padilla, et al.
Cellular and Molecular Neurobiology|June 1, 2011
DNA immunization against amyloid beta 42 has high potential as safe therapy for Alzheimer's disease as it diminishes antigen-specific Th1 and Th17 cell proliferationDoris Lambracht-Washington, Bao-Xi Qu, Min Fu, et al.
Journal of Neuroimmunology|October 6, 2012
A peptide prime-DNA boost immunization protocol provides significant benefits as a new generation Aβ42 DNA vaccine for Alzheimer diseaseDoris Lambracht-Washington, Bao-xi Qu, Min Fu, et al.
Clinical Transplantation|May 21, 2026
Long-Term Outcomes of Renal Transplant Allografts With De Novo DSA in the Setting of Stable FunctionRichard J Knight, Edward A Graviss, Duc T Nguyen, et al.
Clinical Transplantation|June 6, 2017
The detrimental impact of persistent vs an isolated occurrence of de novo donor-specific antibodies on intermediate-term renal transplant outcomesJennifer M Loucks-DeVos, Todd N Eagar, A Osama Gaber, et al.
Journal of Neuroimmunology|September 18, 2014
Testing effects of glatiramer acetate and fingolimod in an infectious model of CNS immune surveillanceCyd Castro-Rojas, Krystin Deason, Rehana Z Hussain, et al.
Pageof 6

Showing results (11-20 of 53) with videos related to

Sort By:
Pageof 6
JAMA|October 29, 2009
DNA beta-amyloid(1-42) trimer immunization for Alzheimer disease in a wild-type mouse modelDoris Lambracht-Washington, Bao-Xi Qu, Min Fu, et al.
Journal of the Neurological Sciences|August 21, 2007
Prion proteins: physiological functions and role in neurological disordersWei Hu, Bernd Kieseier, Elliot Frohman, et al.
Plos One|August 9, 2018
Presenilin1 regulates Th1 and Th17 effector responses but is not required for experimental autoimmune encephalomyelitisMatthew Cummings, Anitha Christy Sigamani Arumanayagam, Picheng Zhao, et al.
Clinical Transplantation|March 20, 2023
Deceased donor vein extension grafts for right living donor kidney transplantationAndrea M Meinders, Richard Knight, Todd N Eagar, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 10, 2004
CTLA-4 regulates expansion and differentiation of Th1 cells following induction of peripheral T cell toleranceTodd N Eagar, Danielle M Turley, Josette Padilla, et al.
Cellular and Molecular Neurobiology|June 1, 2011
DNA immunization against amyloid beta 42 has high potential as safe therapy for Alzheimer's disease as it diminishes antigen-specific Th1 and Th17 cell proliferationDoris Lambracht-Washington, Bao-Xi Qu, Min Fu, et al.
Journal of Neuroimmunology|October 6, 2012
A peptide prime-DNA boost immunization protocol provides significant benefits as a new generation Aβ42 DNA vaccine for Alzheimer diseaseDoris Lambracht-Washington, Bao-xi Qu, Min Fu, et al.
Clinical Transplantation|May 21, 2026
Long-Term Outcomes of Renal Transplant Allografts With De Novo DSA in the Setting of Stable FunctionRichard J Knight, Edward A Graviss, Duc T Nguyen, et al.
Clinical Transplantation|June 6, 2017
The detrimental impact of persistent vs an isolated occurrence of de novo donor-specific antibodies on intermediate-term renal transplant outcomesJennifer M Loucks-DeVos, Todd N Eagar, A Osama Gaber, et al.
Journal of Neuroimmunology|September 18, 2014
Testing effects of glatiramer acetate and fingolimod in an infectious model of CNS immune surveillanceCyd Castro-Rojas, Krystin Deason, Rehana Z Hussain, et al.
Pageof 6